GCM
AUTL

Graham Capital Management’s Autolus Therapeutics AUTL Stock Holding History

Graham Capital Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-147,877
Closed -$241K – 1227
2025
Q3 		$241K Buy
+147,877
New +$289K ﹤0.01% 967

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Graham Capital Management's AUTL Position: Q4 2025 in Review

Graham Capital Management sold out of Autolus Therapeutics (AUTL) in Q4 2025, closing a stake of 147,877 shares — an estimated $241K sold.

Graham Capital Management first reported a position in AUTL in Q3 2025 and held it in 1 quarter. The position peaked at $241K in Q3 2025. 89 funds tracked by Wall St. Rank hold AUTL as of Q4 2025.

  • Graham Capital Management reported no remaining Autolus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Graham Capital Management sold 147,877 Autolus Therapeutics shares in Q4 2025, an estimated $241K.
  • Graham Capital Management first reported a position in Autolus Therapeutics in Q3 2025 and held it in 1 quarter.
  • Graham Capital Management's Autolus Therapeutics position peaked at $241K in Q3 2025.
  • 89 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.